A long-acting intramuscular injectable or depot form of paliperidone was listed on the Pharmaceutical Benefits Scheme (PBS) as Authority required (streamlined) on 1 December 2011*.1,2 It is an alternative to existing long-acting antipsychotics for people with schizophrenia. A maintenance dose is given once a month.3 Paliperidone is the main active metabolite of risperidone2: refer to the product information for information about switching people from oral paliperidone, or oral or injectable risperidone, to injectable paliperidone.3
- Paliperidone palmitate, aqueous suspension for injection, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg, pre-filled syringe (Invega Sustenna): public summary document. Canberra: Australian Government Department of Health and Ageing, 2011. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-paliperidone-nov10 .
- Paliperidone (Invega) for schizophrenia. NPS RADAR April 2008. Sydney: National Prescribing Service, 2008. http://www.nps.org.au/health_professionals/publications/nps_radar/2008/april_2008/paliperidone .
- Invega Sustenna product information. 14 March 2011. http://www.janssen.com.au/files/Products/Invega_Sustenna_PI.pdf .